#USA #New York #Pomerantz LLP #Investor Claims #Acadia Pharmaceuticals

Pomerantz Law Firm Investigates ACADIA Pharmaceuticals Inc.

Pomerantz LLP has recently launched an investigation aimed at addressing claims from investors in ACADIA Pharmaceuticals Inc. (symbol: ACAD), following significant concerns regarding the Company’s business practices and potential securities fraud. Investors who feel they may have been misled are encouraged to reach out to Danielle Peyton, a representative from the law firm, at the provided contact information.

On September 24, 2025, ACADIA released results from its Phase 3 clinical trial, known as the COMPASS PWS trial, which tested the effectiveness of the intranasal carbetocin (also called ACP-101) for addressing hyperphagia in patients diagnosed with Prader-Willi Syndrome (PWS). Unfortunately for the investors, the trial results revealed that the drug did not achieve a statistically significant improvement compared to placebo in the primary endpoint, which measured changes using the Hyperphagia Questionnaire for Clinical Trials (HQ-CT). Not only did the drug fall short of expectations on this critical measure, but it also failed to differentiate itself positively on any of the secondary endpoints assessed during the study.

These unforeseen results prompted ACADIA’s Head of Research and Development to declare that the company would not pursue further investigation into intranasal carbetocin, a decision that undoubtedly shocked many stakeholders and raised alarms about the company’s future. Following the release of this disappointing news, ACADIA's stock took a significant hit, plummeting $2.34 per share or nearly 10%, to finish the trading day at $21.26.

The ramifications of the clinical trial's outcome have led Pomerantz LLP, a law firm with extensive experience in securities litigation, to investigate whether ACADIA Pharmaceuticals and certain members of its management or board might have engaged in unlawful activities or misled investors. Pomerantz, which has a reputation for fighting for the rights of victims of securities fraud and corporate misconduct, has a long-standing history of success in recovering damages on behalf of affected shareholders.

With offices located across several major cities, including New York, Los Angeles, and London, Pomerantz is well-equipped to take on significant class-action cases and represent the interests of investors who may have suffered losses due to corporate misdeeds.

This investigation serves as a strong reminder of the importance of transparency and accountability within publicly traded companies, especially those involved in the pharmaceutical industry. Investors are advised to stay vigilant and informed regarding the developments of ACADIA’s situation and to consider whether it is time to take action based on the findings of this investigation.

As of now, the law office has opened up opportunities for investors to join the class action by reaching out directly. While the full implications of the trial results and the ongoing investigation remain to be seen, the commitment to uncovering any potential wrongdoing is clear. Interested investors should not delay in contacting Pomerantz LLP to discuss their legal rights and potential avenues for recourse.

In conclusion, the unfolding developments involving ACADIA Pharmaceuticals Inc. highlight the critical need for investors to be vigilant regarding their holdings, and to actively seek legal advice when faced with uncertainties surrounding their investments. Pomerantz's probing investigation aims to ensure that investors have the opportunity to pursue justice and recover their losses.

For more information on this investigation and how to join the class action suit, investors should reach out to Pomerantz LLP via phone or email as detailed in their press release.

Pomerantz LLP Contact Information - Phone: 646-581-9980 ext. 7980.